Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?

Rami Sommerstein; Michael M Kochen; Franz H Messerli; Christoph Gräni

doi:10.1161/JAHA.120.016509

Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?

J Am Heart Assoc. 2020 Apr 7;9(7):e016509. doi: 10.1161/JAHA.120.016509. Epub 2020 Apr 1.

Authors

Rami Sommerstein¹, Michael M Kochen², Franz H Messerli^{3

4

5}, Christoph Gräni³

Affiliations

¹ Department of Infectious Diseases Bern University Hospital Bern Switzerland.
² Institute of Family Medicine University of Freiburg Germany.
³ Department of Cardiology Bern University Hospital Bern Switzerland.
⁴ Jagiellonian University Krakow Poland.
⁵ Division of Cardiology Mount Sinai Health Medical Center Icahn School of Medicine New York NY.

No abstract available

Keywords: ACE2; angiotensin II receptor blocker; angiotensin‐converting enzyme inhibitor; coronavirus disease 2019; epidemiology; infectious diseases.

MeSH terms

Angiotensin Receptor Antagonists / adverse effects
Angiotensin Receptor Antagonists / pharmacology*
Angiotensin-Converting Enzyme 2
Angiotensin-Converting Enzyme Inhibitors / adverse effects
Angiotensin-Converting Enzyme Inhibitors / pharmacology*
Betacoronavirus / drug effects*
COVID-19
Cardiovascular Diseases* / complications
Cardiovascular Diseases* / drug therapy
Comorbidity
Coronavirus Infections / complications*
Coronavirus Infections / mortality
Disease Notification
Humans
Pandemics
Peptidyl-Dipeptidase A / drug effects
Peptidyl-Dipeptidase A / metabolism
Pneumonia, Viral / complications*
Pneumonia, Viral / mortality
Risk Factors
SARS-CoV-2
Severity of Illness Index

Substances

Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Peptidyl-Dipeptidase A
ACE2 protein, human
Angiotensin-Converting Enzyme 2